Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Adicet Bio (NASDAQ:ACET), a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7 ...

Net loss was $23.0 million, or $0.31 per basic and diluted share, for the second quarter of 2025. This net loss includes non-cash charges of $3.4 million that consisted primarily of share-based ...

Using data from over 1.5 million patients from 47 studies, the researchers analysed the association between four autoimmune ...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Reports Q2 revenue $20.9M, consensus $12.92M. “We are encouraged by AUCATZYL’s early launch performance in the U.S., driven by physician ...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of ...

Novartis announces both ianalumab phase III trials meets primary endpoint in patients with Sjögren’s disease: Basel Tuesday, August 12, 2025, 14:00 Hrs [IST] Novartis announced ...

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients ...

Around four million people in the UK live with an autoimmune condition, according to a major study published in The Lancet.